(lp0
S'Earnings Reaction History: Lexicon Pharmaceuticals Inc., 33.3% Follow-Through ... Nasdaq - Mar 3, 2017 Lexicon Pharmaceuticals Inc.  is due to issue its quarterly earnings report in the upcoming extended-hours session.'
p1
aS"FDA OKs Lexicon Pharma's telotristat etiprate for carcinoid syndrome Seeking Alpha - Feb 28, 2017 The FDA approves Lexicon Pharmaceuticals'  XERMELO  250 mg for the treatment of carcinoid syndrome diarrhea, in combination with somatostatin therapy  in adult patients inadequately controlled with SSA therapy.FDA approves Lexicon Pharma's carcinoid syndrome diarrhea drug - ReutersLexicon Pharmaceuticals'  Xermelo Approved by FDA - Economic Calendar"
p2
aS'Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 ... PR Newswire  - Mar 3, 2017 THE WOODLANDS, Texas, March 3, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. , today reported financial results for the three months and year ended December 31, 2016 and provided an overview of key milestones for the&nbsp;...Lexicon Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 02 - Equities.comWedbush Boosts Lexicon Pharmaceuticals, Inc.  Price Target to $38.00 - Chaffey Breeze'
p3
aS'Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference PR Newswire  - Mar 6, 2017 THE WOODLANDS, Texas, March 6, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc.  announced today that Lexicon management will present at the Cowen and Company 37th Annual Healthcare Conference on Wednesday, March 8,&nbsp;...'
p4
aS'Lexicon Pharmaceuticals Inc.  Moves Higher on Volume Spike for February 27 Equities.com - Feb 27, 2017 Lexicon Pharmaceuticals Inc.  traded on unusually high volume on Feb. 27, as the stock gained 4.64% to close at $16.45.Lexicon Pharmaceuticals  Stock: FDA Approves XERMELO - CNA Finance '
p5
aS'Estimating the intrinsic value of Lexicon Pharmaceuticals Inc  Simply Wall St - Mar 3, 2017 How far off is Lexicon Pharmaceuticals  to its intrinsic value? I am going to take a look now using a method called discounted cash flow or DCF.'
p6
aS'Lexicon: Xermelo Approved, Provides Valuation Floor Seeking Alpha - Mar 7, 2017 Lexicon  announced the approval of telotristat ethyl  last week. The stock briefly touched $18 in after-hours trading yesterday and closed below $16 today.'
p7
aS'Lexicon To Present At The Barclays Global Healthcare Conference PR Newswire  - Mar 9, 2017 Lexicon Pharmaceuticals, Inc.  announced today that Lexicon management will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 3:50 p.m.'
p8
aS'Lexicon Pharmaceuticals  Shares Cross Below 200 DMA Nasdaq - Mar 13, 2017 In trading on Monday, shares of Lexicon Pharmaceuticals, Inc.  crossed below their 200 day moving average of $15.53, changing hands as low as $15.45 per share.'
p9
aS'Hot Stocks Among Investors: Lexicon Pharmaceuticals, Inc. , Adamis ... Post Analyst - Mar 17, 2017 Lexicon Pharmaceuticals, Inc.  has made its way to a 12-month gain of 35.19%. Turning to Adamis Pharmaceuticals Corporation , its shares were trading at $4.45 a retreat of $-0.1, on the trading floor.News Recap: Instructure  , Lexicon Pharmaceuticals, Inc.  - NYSE Journal Zacks Rank on Lexicon Pharmaceuticals, Inc.  based on Estimated Earnings - Energy Index'
p10
a.